Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. - Wikidata - wikimedia - TriplyDB

Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.

Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.

http://www.wikidata.org/entity/Q44225009

about

Role of NADPH oxidases in liver fibrosis.Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats ANG II receptor subtype 1a gene knockdown in the subfornical organ prevents increased drinking behavior in bile duct-ligated rats The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation.NADPH oxidase mediated oxidative stress in hepatic fibrogenesis Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project.Antifibrotic agents for liver disease.Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis.Intracerebroventricular losartan infusion modulates angiotensin II type 1 receptor expression in the subfornical organ and drinking behaviour in bile-duct-ligated rats.NOX in liver fibrosis Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.Bioconjugation of oligonucleotides for treating liver fibrosis.Managing pediatric hepatitis C: current and emerging treatment options.Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies.Role of renin-angiotensin system in liver diseases: an outline on the potential therapeutic points of intervention.ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2,9 Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.Inhibitory effect of Huangqi Zhechong decoction on liver fibrosis in rat.Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats.Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension.Reversal of liver fibrosis.Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver.Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni.Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.Halofuginone can worsen liver fibrosis in bile duct obstructed rats.Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis.Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.Addressing liver fibrosis with liposomes targeted to hepatic stellate cells.Angiogenesis in Schistosoma haematobium-associated urinary bladder cancer.The selective mineralcorticoid receptor (MR) antagonist eplerenon prevents decompensation of liver cirrhosis.Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion

P2860

Q33632736-393DE245-50FD-46F7-A228-C538B5133531 Q33787922-C451841A-1431-4CD6-9CFA-5BDAC9256F66 Q34201130-4F0D17A3-DAD5-4D05-B45F-EE38B0B9B963 Q35124395-07723573-3207-4975-96BE-1AFF8DA802A8 Q35150772-AAE6FE10-B5C4-45E4-9E9D-4B082EBE18AE Q35276739-1CF711A0-2B37-42B0-ABB7-FDB8E30DEDC9 Q35437089-B999DE92-8108-4E5A-9F64-BB9CF9D9CBD2 Q35833225-ACF8B0C2-EEDA-4B7E-95E8-02168AA4F4DF Q36206673-2F936B05-C782-4317-A00F-EEF81BCE2455 Q36376477-9AF6B49E-0478-4EF3-913F-0B16069E3E0E Q36503291-F1DB878C-420A-492D-BD63-4979C973C2CA Q36524368-42F364C2-06B3-4AE3-9E99-018501068D14 Q36711459-D4791CA3-60E1-487C-A742-C957A38EA3BA Q36832562-A9CD3FF4-0C85-4F35-BC2A-9288DA518D35 Q36924883-5C413295-584A-4D01-ABF6-E51F4F85DAB3 Q37043515-3A18C35C-D5C2-4DE6-918C-684E2D97D19A Q37316248-1605C89E-C55E-4C67-B13C-9AFB5735070A Q37355850-D02D70E8-DD11-4A37-8EDF-8CBE319C2985 Q38879747-AF7D5CFA-8923-49B3-A142-F288F4429377 Q39677068-07806C09-F769-4416-827F-6466B0FDE5AF Q41029212-2C5BD60F-5D74-4CC8-B954-81525616764E Q41663953-51FCEDD1-98F5-42D0-B55B-79C96C62D533 Q41893446-C42E5E0C-A182-43A8-BB53-B0E4F58FD830 Q42109164-FF70F491-CC96-4056-94C0-09193E8D8A37 Q42591497-D8EDA16D-EEC9-4745-99EA-8DB7EEABB839 Q43104809-036B4838-9223-4B55-AE7B-572B8A688EE9 Q43176982-F17A6264-1950-4E89-B03F-6162F5BAEA41 Q44457672-3B328ABA-36BC-4DDC-8227-D51D6EE0C2BE Q44574643-E9400E66-DDBA-46F3-9A5C-A2F144C9538A Q44667862-BE62C89D-35FE-461C-86A4-21984E5BD0DD Q45105191-ABF0B4DC-7259-4347-9BB0-2583E639F215 Q46213897-CCA39468-B623-4BA9-ABCC-54EC94F2657C Q46504451-4EE5626F-9285-4EBD-BE39-B17B311A3C49 Q46636382-A00A7D6F-7A3D-46AE-83D1-58EA39B01E69 Q46890423-F8DB52BD-C37B-4BAD-801B-57C249CFE0B7 Q47727139-336C960E-C35F-4373-8D16-A6980EF8339B Q52570905-0377C7B4-4333-4727-8278-7ADB092D44F3 Q57108060-CBCF9EAD-91CF-4412-A0AC-16BA1173A52A

P2860

Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.

http://www.wikidata.org/entity/Q44225009

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@en

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@nl

type

label

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@en

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@nl

prefLabel

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@en

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@nl

P1433

Q44225009-3CA9AE0F-06F9-4C03-A506-BD4B153B9EA8

P1476

Q44225009-0F019446-7B87-463B-9539-928AF099A466

P2093

Q44225009-17804401-700F-4077-87D2-661AC56EEA8D

Q44225009-414EFAA7-78C3-4A4D-A6BE-85E1F8950C2C

Q44225009-715EFD36-8FB7-4B86-A0F0-186EFA604E47

Q44225009-995373CF-F736-4402-9D52-2DED845F700B

Q44225009-B386DA17-0FDB-4FCB-A8C9-0C0BBB1EA4A2

Q44225009-B70C8D5F-88B5-4A19-8A15-0B739DF6E9B4

Q44225009-C788F9C0-E492-4FDD-BDAC-56DAA9280D86

Q44225009-D35E10FF-EB7F-493C-B8F3-D36777A84882

Q44225009-E8548F98-28BB-4C71-8F29-D141A84B50FE

Q44225009-FB98B716-C418-4723-9BF9-F59BE34F8E15

P304

Q44225009-E5A2FFAE-B13C-4B07-A714-DB50627066AC

P31

Q44225009-6E42A776-8577-4E3A-A7A8-B5E1B74C1C46

P356

Q44225009-18AC491D-4B9B-47F6-B4E8-23E707AACB10

P433

Q44225009-C6E2CA1D-3D5A-4061-BA4B-B186D83DE3F4

P478

Q44225009-4CCA8263-3329-4FD1-A0CD-85598566BE79

P50

Q44225009-CA8D2F9A-87F0-40FF-97F7-1B17172480B1

P577

Q44225009-9B37BBFA-01CF-4FE6-923A-E6522F28C93E

P698

Q44225009-10E134D9-A93A-467A-B717-C0E038D54791

P921

Q44225009-D2982D77-C647-4BEF-9549-1D5465581763

P356

S0168-8278(02)00307-0

P1433

Journal of Hepatology

P1476

Hemodynamic and antifibrotic e ...... is and/or portal hypertension.

@en

P2093

Daniel Chappard

http://www.w3.org/2001/XMLSchema#string

Eric Vuillemin

http://www.w3.org/2001/XMLSchema#string

Frédéric Moal

http://www.w3.org/2001/XMLSchema#string

Frédéric Oberti

http://www.w3.org/2001/XMLSchema#string

Jianhua Wang

http://www.w3.org/2001/XMLSchema#string

Jérôme Roux

http://www.w3.org/2001/XMLSchema#string

Nary Veal

http://www.w3.org/2001/XMLSchema#string

Olivier Douay

http://www.w3.org/2001/XMLSchema#string

Vincent Croquet

http://www.w3.org/2001/XMLSchema#string

Yves Gallois

http://www.w3.org/2001/XMLSchema#string

P304

773-780

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0168-8278(02)00307-0

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12445418

http://www.w3.org/2001/XMLSchema#string

P921